Search the Newsreel

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …

Estrella adds fourth site to EB103 lymphoma trial By Investing.com

Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …

Prelude Therapeutics 2Q Loss/Shr 14c >PRLD

Prelude Therapeutics reported a second-quarter loss per share of 14 cents. This financial update is significant for investors tracking PRLD.

Reliance Chemotex Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Prelude Therapeutics reports Q2 2026 results: $5.7M revenue, $13.9M net loss, $155.2M cash

Prelude Therapeutics announced its Q2 2026 financial results, reporting $5.7 million in revenue and a net loss of $13.9 million. The company holds $155.2 million in cash and equivalents, with a projected cash runway extending into Q2 2028. Key business highlights include progress in …

RELX PLC : JP Morgan remains its Buy rating

JP Morgan has reiterated its Buy rating for RELX PLC, with analyst Daniel Kerven maintaining a target price of GBX 5070. This reaffirmation suggests continued confidence in the information and analytics provider's stock performance.

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Relay Therapeutics, Inc. (NASDAQ:RLAY) recently released its second-quarter results, showing revenue of US$350k, 56% less than analysts expected, and losses of US$0.41 per share, which were larger than modeled. Following these results, analysts have cut their 2026 revenue estimates to US$10.2m and increased their …

11 Best New Cracker Barrel Fall Kitchen and Dining Finds Under $30

This article highlights 11 new fall kitchen and dining items available at Cracker Barrel, all priced under $30. The selection includes Halloween-themed decorations like a haunted house cookie jar and ghost cutting board, as well as general fall and early Christmas items such as …

Mizuho reiterates Relmada stock rating after manufacturing delay

Mizuho has reiterated an Outperform rating and $19.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD) despite concerns over manufacturing delays for its NDV-01 program. The stock has seen a significant decline since these concerns emerged, though it has surged over 700% in the past …

Tenable Holdings' (NASDAQ:TENB) Strong Earnings Are Of Good Quality

Reliance Chemotex re-appoints Sanjiv Shroff as MD for 3 years

Reliance Global Group Ord Shs (EZRA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Reliance Global Group Ord Shs (EZRA), detailing expected future EPS and revenue growth estimates. It includes a snapshot of the stock's current trading information, market capitalization, and a list of peer companies for comparison. The content also …

Perella Weinberg Partners (PWP) Beat Expectations, Is The Premium Valuation Already Priced In?

G-III Apparel Group Financial Analyst Salaries in Las Cruces, NM

The average Financial Analyst at G-III Apparel Group in Las Cruces, NM earns an estimated $88,288 annually, comprising a base salary of $78,705 and a bonus of $9,583. This compensation is slightly higher than the US average for the role. The article also details …

KAREL ELEKTRONIK - KAP Haberleri - 2026-08-10 tarihli

RELX PLC (PK) RLXXF Titulares - Distribuição de Posse de Ações

Does JBT Marel’s (JBTM) Steady Guidance And Buybacks Reveal A New Capital Allocation Playbook?

JBT Marel Corporation reported stronger Q2 2026 results with higher sales and net income, reaffirming its full-year revenue guidance of US$3.99 billion to US$4.07 billion and GAAP diluted EPS of US$4.20 to US$4.70. The company also announced a US$26 million share buyback and a …

Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.4% in Relay Therapeutics, Inc. This stake, totaling 14,106,187 shares, is held directly by the Master Fund. All reporting persons share voting and dispositive power over …

RELX PLC (REL) Acquires 903,327 Shares in Early August 2026, Treasury Holdings Reach 79.6 Million

RELX PLC (REL) has acquired 903,327 of its ordinary shares between August 3 and 7, 2026, through ABN AMRO Bank N.V. on the London Stock Exchange. These shares will be held as treasury shares and are part of an ongoing buyback program that has …

Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates

The user provided an incomplete article content ("Document") and thus a meaningful summary cannot be generated. Similarly, the cleaned content cannot be provided as the full article text is missing.

Citizens Jmp Increases Relay Therapeutics (NASDAQ:RLAY) Price Target to $26.00

Citizens raises Relay Therapeutics stock price target on progress

Citizens has increased its price target for Relay Therapeutics (NASDAQ:RLAY) shares to $26.00 from $21.00, maintaining a Market Outperform rating, based on significant progress in breast cancer treatment development. The company's stock has shown strong performance, surging 514% over the past year, and its …

Dimensional Fund Advisors LP Has $11.31 Million Holdings in Cracker Barrel Old Country Store, Inc. $CBRL

Dimensional Fund Advisors LP reduced its stake in Cracker Barrel Old Country Store, Inc. (NASDAQ:CBRL) by 17.5% in the first quarter, now holding 402,235 shares valued at $11.31 million. Despite the reduction, institutional investors and hedge funds own 96.01% of the stock. Cracker Barrel …

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages

Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a "Moderate Buy" consensus rating from 14 analysts, with an average 12-month price target of $25.17, exceeding its current share price of $19.77. Despite recent positive analyst actions like price target increases, the company missed its latest quarterly …

The 5 Most Interesting Analyst Questions From Perella Weinberg’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From Perella Weinberg's Q2 Earnings Call Perella Weinberg's second quarter saw flat year-over-year sales but outperformed market expectations, which was met by a significant upward move in the share price. Management attributed the result to a notable acceleration …

JBT Marel Corporation Revenue Breakdown – NYSE:JBTM

JBT Marel Corporation (NYSE: JBTM) generated $3.80 billion USD in revenue last year, with its top-performing segment, Prepared Food and Beverage Solutions, contributing $2.08 billion USD. The largest regional contribution came from Europe, Middle East and Africa, accounting for $1.52 billion USD.

2 Things Relay Therapeutics (RLAY) Results Say About Its 4.9x P B Valuation

Relay Therapeutics reported a wider net loss and lower revenue in Q2 2026, leading to a slight pullback in its shares recently, though the stock has seen significant year-to-date gains. The company's P/B ratio of 4.9x is below its peers but still considered expensive …

Dorel Industries Q2 Earnings Call Highlights

Key Points Interested in Dorel Industries Inc? Here are five stocks we like better. Dorel's Q2 revenue fell 14.7% to $42.9 million lower year over year, but the operating loss improved to $24.3 million from $37.2 million. Excluding restructuring and foreign-exchange effects, management said …

Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Relmada Therapeutics (NASDAQ:RLMD) announced its quarterly earnings, reporting an EPS loss of $0.11, significantly beating analysts' expectations of a $0.20 loss by $0.09. Despite the positive earnings surprise and a strong financial position with $217.7 million in cash expected to fund operations through 2029, …

G-III Apparel Group | 8-K: Current report

This article is an 8-K filing from G-III Apparel Group, indicating a current report has been filed. The content of the report is not detailed in this snippet but signals a significant event or update from the company.

Trade Alert: CEO, Partner of New York & Director Of Perella Weinberg Partners Andrew Bednar Has Sold Stock

Andrew Bednar, CEO, Partner of New York & Director at Perella Weinberg Partners, recently sold US$4.1 million worth of company stock, reducing his holding by 26%. While another insider also sold shares in the last year, there have been no insider purchases. Insider ownership …

JBT Marel (JBTM) Following Earnings Guidance And Dividend Update, Is Valuation Back In Focus

Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Relay Therapeutics (NASDAQ:RLAY) reported a quarterly loss of $0.41 per share, missing analysts' estimates by $0.02, with revenue of $0.35 million falling short of the $0.96 million consensus. Despite missing estimates, shares rose to $19.77, near its 52-week high, and analysts maintain a "Moderate …

The Bull Case For Cracker Barrel (CBRL) Could Change Following David Deno’s Appointment As CEO And Director

Cracker Barrel Old Country Store has appointed David Deno as CEO and Director, a move expected to significantly influence the company's turnaround efforts. Deno brings extensive experience from various restaurant and retail brands, which could help address the execution risks associated with Cracker Barrel's …

Is It Smart To Buy Reliance, Inc. (NYSE:RS) Before It Goes Ex-Dividend?

Why (AMBA) Price Action Is Critical for Tactical Trading

This article analyzes Ambarella Inc. (NASDAQ: AMBA) for tactical trading, highlighting a strong near- and mid-term sentiment but a weak long-term outlook. It identifies key price levels, support, and resistance, and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, tailored …